DJ Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
22-Jul-2025 / 07:02 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Aubagne, July 22, 2025
Information on Document Availability
The report on the first half 2025 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations
It contains the following information:
- Business development for the period of January to June 2025 as well as the 2025 full year forecast for the
Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended June 30, 2025
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner to the biopharmaceutical industry. As a provider of
innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications,
such as cell and gene therapies, more safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are
listed on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales
entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through
acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros.
More than 9,900 employees work for customers around the globe.
Contact
Petra Müller
Head of Investor Relations
+49 (0)551.308.6035
petra.mueller2@sartorius.com
=----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file
File: 2025_SSB_Document availability H1_en
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: sartorius.presse@sartorius.com
Internet: www.sartorius.com
ISIN: FR0013154002
Euronext DIM
Ticker:
AMF Category: Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly
financial report
EQS News ID: 2172692
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
2172692 22-Jul-2025 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2172692&application_name=news&site_id=dow_jones%7e%7e%7ebed8b539-0373-42bd-8d0e-f3efeec9bbed
(END) Dow Jones Newswires
July 22, 2025 01:02 ET (05:02 GMT)
© 2025 Dow Jones News
